446 THE EFFECT OF THE MEDICATIONS BY ALPHA-1 BLOCKERS AND 5 ALPHA REDUCTASE INHIBITORS FOR CHRONIC PROSTATIC INFLAMMATION.

446 THE EFFECT OF THE MEDICATIONS BY ALPHA-1 BLOCKERS AND 5 ALPHA REDUCTASE INHIBITORS FOR CHRONIC PROSTATIC INFLAMMATION.

Bibliographic Details
Main Authors:	S Inamura, T Shinagawa, H Kobayashi, M Tsutsumiuchi, M Seki, M Taga, M Fukushima, H Ito, M Kobayashi, O Yokoyama, N Terada
Format:	Article
Language:	English
Published:	Elsevier 2022-06-01
Series:	Continence
Online Access:	http://www.sciencedirect.com/science/article/pii/S2772973722007093

Similar Items

164 ANTICHOLINERGIC BURDEN DECREASES VOIDING EFFICIENCY IN THE ELDERLY FACILITIES.
by: Y Okumura, et al.
Published: (2022-06-01)

Effects of prostatic inflammation on LUTS and alpha blocker treatment outcomes
by: Ha Na Lee, et al.
Published: (2014-06-01)

The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia
by: Eric H. Kim, et al.
Published: (2018-01-01)

DIFFERENCES IN THE EFFECTIVENESS OF SELECTIVE ALPHA BLOCKER THERAPY COMBINED WITH 5-ALPHA REDUCTASE INHIBITOR ON IPSS VALUE OF BPH LUTS PATIENTS
by: Septa Surya Wahyudi, et al.
Published: (2020-07-01)

Prostate Cancer Mortality and Use of 5-Alpha Reductase Inhibitors
by: Cara A. Foldes, et al.
Published: (2020-04-01)

Role of 5-alpha reductase inhibitors in the prevention of prostate cancer
by: Bhupendra P Singh, et al.
Published: (2011-01-01)

EFFECTIVENESS OF 5-ALPHA-REDUCTASE INHIBITORS IN PATIENTS WITH PROSTATIC INTRAEPITHELIAL NEOPLASIA OF PERIPHERAL PROSTATE ZONE
by: M. P. Мelnychuk
Published: (2019-04-01)

5-alpha reductase inhibitors and MRI prostates: actively reducing prostate sizes and ambiguity
by: Ziting Wang, et al.
Published: (2023-04-01)

Treatment Patterns in Alpha-Blocker Therapy for Benign Prostatic Hyperplasia
by: Michael J. Schoenfeld MA, et al.
Published: (2014-05-01)

Effect of 5-Alpha Reductase Inhibitors on Magnetic Resonance Imaging and Prostate Cancer Detection
by: Juan Morote, et al.
Published: (2024-02-01)

ROLE OF MONOTHERAPY ALPHA BLOCKERS VERSUS COMBINATION ALPHA BLOCKERS AND ANTICHOLINERGICS IN THE MANAGEMENT OF LOWER URINARY TRACT SYMPTOMS/BENIGN PROSTATIC HYPERPLASIA
by: Muhammad Tanveer Sajid, et al.
Published: (2020-04-01)

ROLE OF ALPHA BLOCKER IN URETERORENOSCOPY.
by: Noreen Anwar, et al.
Published: (2021-12-01)

Silodosin — a safer alpha-blocker targeting benign prostatic hyperplasia
by: Karen Koch
Published: (2015-09-01)

Alpha blockers: A relook at phenoxybenzamine
by: Sambhunath Das, et al.
Published: (2017-01-01)

Risk of gynecomastia and breast cancer associated with the use of 5-alpha reductase inhibitors for benign prostatic hyperplasia
by: Hagberg KW, et al.
Published: (2017-02-01)

Use of alpha-blockers to relieve lower urinary tract symptoms in benign prostatic hyperplasia
by: GG Krivoborodov
Published: (2014-12-01)

Use of alpha-blockers and the risk of hip/femur fractures.
by: Souverein, P, et al.
Published: (2003)

Sexual Dysfunctions Related to Drugs Used in the Management of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Narrative Review on α-Blockers and 5-Alpha Reductase Inhibitors
by: Antonio La Torre, et al.
Published: (2021-07-01)

Are there any positive effects of TNF-alpha blockers on bone metabolism?
by: A. Sulli, et al.
Published: (2011-09-01)

Endothelial alpha globin is a nitrite reductase
by: T. C. Stevenson Keller, et al.
Published: (2022-10-01)

Prostate cancer patients can benefit from 5-alpha-reductase inhibitor treatment: a meta-analysis
by: Tuo Deng, et al.
Published: (2020-06-01)

Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis.
by: Jae Heon Kim, et al.
Published: (2018-01-01)

Is prostatic artery embolization a relevant treatment after a failed alpha-blocker monotherapy?
by: Souhil Lebdai
Published: (2023-09-01)

Intravescical prostatic protrusion is a predictor of alpha blockers response: results from an observational study
by: L. Topazio, et al.
Published: (2018-02-01)

Evaluation of ultrasonographic predictors of alpha-blocker mono-therapy failure in symptomatic benign prostatic enlargement
by: Mohamed Radwan, et al.
Published: (2021-01-01)

Evaluation of apoptosis indexes in currently used oral alpha-blockers in prostate: a pilot study
by: Mehmet Demir, et al.

Use of 5-Alpha Reductase Inhibitors in Dermatology: A Narrative Review
by: Mariana Escamilla-Cruz, et al.
Published: (2023-07-01)

Effect of alpha1-blockers on stentless ureteroscopic lithotripsy
by: Jianguo Zhu, et al.
Published: (2016-02-01)

Symptomatic benign prostatic hyperplasia: the role of 5-alpha-reductase inhibitors in the prevention of acute urinary retention and surgical therapy
by: Norma Marigliano, et al.
Published: (2012-01-01)

The Risk of Venous Thromboembolism (VTE) in Men with Benign Prostatic Hyperplasia Treated with 5-Alpha Reductase Inhibitors (5ARIs).
by: Ayodele O, et al.
Published: (2021-08-01)

Predictive factors for alpha blocker use after transurethral prostatectomy: Can preoperative urodynamic outcome predict alpha blocker medication after surgery?
by: Sung Jin Kim, et al.
Published: (2022-01-01)

Predictive factors for alpha blocker use after transurethral prostatectomy: Can preoperative urodynamic outcome predict alpha blocker medication after surgery?
by: Sung Jin Kim, et al.
Published: (2022-01-01)

5-alpha-reductase deficiency: a case report
by: Diana Mettadewi Jong, et al.
Published: (2016-10-01)

Is prostatic artery embolization a relevant treatment after a failed alpha-blocker monotherapy?—Authors’ reply
by: Marc Sapoval, et al.
Published: (2023-09-01)

Efficacy and safety of a combined use of alpha1-blocker doxazosin and phosphodiesterase-5 inhibitor udenafil in patients with benign prostatic hyperplasia
by: S. K. Martazinova, et al.
Published: (2014-11-01)

Efficacy and safety of a combined use of alpha1-blocker doxazosin and phosphodiesterase-5 inhibitor udenafil in patients with benign prostatic hyperplasia
by: S. K. Martazinova, et al.
Published: (2014-11-01)

KIsspeptin correction capabilities of the reproductive status upon application of the blockers and activators of alpha-adrenergic receptors
by: M Matvienko, et al.
Published: (2016-07-01)

Docking and Molecular Dynamics Identify Leads against 5 Alpha Reductase 2 for Benign Prostate Hyperplasia Treatment
by: Selina A. Saah, et al.
Published: (2023-01-01)

Anti-oncogenic effects of dutasteride, a dual 5-alpha reductase inhibitor and a drug for benign prostate hyperplasia, in bladder cancer
by: Jaekwon Seok, et al.
Published: (2023-02-01)

Evaluation of Sex Hormone Levels in Benign Prostatic Hyperplasia Patients Treated with 5 Alpha-Reductase Inhibitor (Finasteride) in Amara city/Iraq
by: Hashim et al.
Published: (2020-03-01)